예측 기간(2025-2034) 동안 VBI-S(Vivacelle Bio), Enibarcimab(AdrenoMed), ZEVTERA(Ceftobiprole Medocaril, Basilea Pharmaceutica)와 같은 파이프라인 후보물질이 패혈증 시장 규모 확대를 촉진할 것으로 예상됩니다.
패혈증 시장은 승인된 치료제가 적고, 미충족 수요가 높다는 제약이 있습니다. 그러나 파이프라인의 혁신과 인지도 향상으로 인해 점진적인 성장과 향후 치료 옵션의 개선이 예상됩니다. 예측 기간(2025-2034년)에 시장에 진입하는 위의 유망한 후보 약물에 대해 언급하기에는 너무 이르지만, 이 시장의 미래는 밝을 것으로 예상됩니다. 궁극적으로 이러한 약제들이 향후 몇 년 안에 패혈증 정세에 큰 변화를 가져올 것으로 보입니다. 이 치료 영역은 전 세계적인 의료비 증가로 인해 향후 몇 년 동안 큰 폭의 플러스 전환이 예상됩니다.
미국의 패혈증(Sepsis) 시장에 대해 조사 분석했으며, 시장 규모 예측, 현재 관리 기술, 새로운 치료법, 신약 프로파일 등의 정보를 전해드립니다.
Report Summary
The section dedicated to drugs in the sepsis report provides an in-depth evaluation of late-stage pipeline drugs (Phase III and Phase II) related to sepsis. The drug chapters section provides valuable information on various aspects related to clinical trials of sepsis, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting sepsis.
Marketed Therapies
TYZAVAN (vancomycin): Hikma Pharmaceuticals
TYZAVAN is a glycopeptide antibiotic indicated for treating septicemia, as well as infective endocarditis, skin and soft tissue infections, bone infections, and lower respiratory tract infections in adults and pediatric patients aged one month and older, when appropriate dosing with this formulation is possible.
The name TYZAVAN, short for "time-saving vancomycin," highlights its goal of providing fast and straightforward treatment when time is critical. It is the only FDA-approved vancomycin product on the market that can be stored at room temperature and requires no compounding, thawing, activation, or dilution-streamlining preparation and enabling quicker administration.
In July 2025, Hikma Pharmaceuticals announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name TYZAVAN.
Emerging Therapies
VBI-S: Vivacelle Bio
VBI-S is Vivacelle Bio's lead Phase III candidate for hypovolemic septic shock. Using patented phospholipid nanoparticle technology, it redistributes nitric oxide to raise blood pressure, improve organ perfusion, and support recovery. Its room-temperature stability makes it practical for use across diverse healthcare settings.
A Phase II trial of VBI-S demonstrated 100% efficacy, with the treatment resulting in elevated blood pressure in hypovolemic septic shock patients who are refractory to therapy. In addition to venture capital, Vivacelle has garnered backing and financial support from the US Department of Defense and the National Institutes of Health.
In September 2024, Vivacelle Bio announced the enrollment of the first patient in a Phase III trial for its lead therapy, VBI-S, a phospholipid nanoparticle-based treatment targeting both absolute and relative hypovolemia caused by septic shock. The company also launched six trial sites for the study.
Enibarcimab: AdrenoMed
Enibarcimab (formerly Adrecizumab) is a humanized, non-neutralizing monoclonal antibody directed against Adrenomedullin (ADM), a key mediator of vascular integrity. By binding to ADM, it elevates circulating levels of bioactive ADM, thereby strengthening endothelial function and mitigating sepsis-related vascular leakage.
Enibarcimab, a first-in-class therapy, aims to restore vascular stability in septic shock by addressing a key mechanism responsible for organ failure and death. Its development utilizes a precision medicine approach, using biomarker-guided patient selection. AdrenoMed is also preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach
In April 2024, AdrenoMed was granted US FDA Fast Track Designation (FTD) for Enibarcimab as a treatment for septic shock.
During the forecast period (2025-2034), pipeline candidates such as VBI-S (Vivacelle Bio), Enibarcimab (AdrenoMed), ZEVTERA (Ceftobiprole Medocaril, Basilea Pharmaceutica), and others are expected to drive the rise in sepsis market size.
The sepsis market is limited by few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to drive modest growth and improve future therapeutic options. Even though it is too soon to comment on the above-mentioned promising candidate to enter the market during the forecast period (2025-2034), it is safe to assume that the future of this market is bright. Eventually, these drugs will create a significant difference in the landscape of sepsis in the coming years. The treatment space is expected to experience a significant positive shift in the coming years owing to the improvement in healthcare spending worldwide.
Sepsis Understanding and Treatment
Sepsis Overview
Sepsis is a critical, life-threatening condition that occurs when the body's response to an infection becomes harmful, leading to damage of vital organs and potentially resulting in death. It represents an excessive and toxic immune reaction to infection. Similar to a heart attack or stroke, sepsis is a medical emergency that demands immediate diagnosis and treatment. If not managed promptly, it can progress to severe sepsis or septic shock.
While sepsis can affect anyone, some groups are at greater risk. These include adults over 65, individuals with chronic health conditions like kidney disease, diabetes, lung disease, or cancer, and those with weakened immune systems due to medications or HIV/AIDS. Others at higher risk include people recently hospitalized or seriously ill, those with a history of sepsis, infants under one year old, and pregnant women experiencing complications during pregnancy or childbirth.
Sepsis Diagnosis
Sepsis is primarily diagnosed through clinical evaluation, supported by lab and microbiological findings. It reflects a dysregulated immune response to infection, leading to systemic inflammation and organ dysfunction. Because there's no single definitive test, diagnosis relies on vital signs, lab markers (e.g., lactate, creatinine, bilirubin), and cultures, particularly blood cultures, though these can be negative or contaminated in many cases. Early detection tools like SIRS and qSOFA are used, though each has limitations, and no gold standard currently exists.
A thorough sepsis workup includes evaluating systemic signs (fever, tachycardia, abnormal WBC), organ dysfunction (e.g., low platelets, elevated INR, lactate), and identifying infection sources via imaging and cultures. Key tests include CBC, CMP, lactate, coagulation panels, and imaging (e.g., chest X-ray, CT, MRI). Additional tests like procalcitonin and CRP may support diagnosis. The Sepsis-2 criteria and SEP-1 core measures guide clinicians in assessing organ dysfunction and severity.
Sepsis Treatment
Effective management of sepsis and septic shock requires early recognition and rapid intervention, following evidence-based guidelines like those from the Surviving Sepsis Campaign (SSC). Key components include prompt initiation of broad-spectrum intravenous antibiotics-ideally within one hour-after obtaining blood cultures, fluid resuscitation with crystalloids, and hemodynamic support using vasopressors like norepinephrine to maintain a MAP of 65 mmHg. Additional agents, such as vasopressin or epinephrine, may be added in refractory cases or when cardiac dysfunction is present. Antifungals are used when invasive fungal infection is suspected, and combination therapy may be needed for patients at risk of multidrug-resistant organisms.
Adjunctive therapies like corticosteroids are considered in septic shock unresponsive to fluids and vasopressors, with hydrocortisone (200 mg/day) being the standard. Steroids enhance vascular tone and support circulating volume through glucocorticoid and mineralocorticoid effects. Emerging adjuncts, including vitamin C and thiamine, have shown potential in reducing mortality and organ failure when used alongside steroids, as demonstrated in studies. These therapies aim to modulate immune responses and correct metabolic imbalances common in severe sepsis.
The sepsis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by incident cases, origin-specific cases, gender-specific cases, severity-specific cases, total treated cases and refractory cases of sepsis in the United States from 2020 to 2034.
KOL Views
To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.
We have reached out to industry experts to gather insights on various aspects of sepsis, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US.
Our team of analysts at Delveinsight connected with more than 10 KOLs across the US. We contacted institutions such as the University of Pittsburgh, the Ohio State University, etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the sepsis market, which will assist our clients in analyzing the overall epidemiology and market scenario.
Qualitative Analysis
We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for sepsis, one of the most important primary endpoints was achieving Sepsis Support Index (SSI), Sequential Organ Failure Assessment (SOFA) score, Mean Arterial Blood Pressure (MAP), etc. Based on these, the overall efficacy is evaluated.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.